JPRN-UMIN000000823已完成3 期
Phase III Randomized Study of Imatinib therapy in chornic phase chronic myeloid leukemia comparing standard dose-escalation with progressive dose-escalation (JALSG CML207study) - Phase III Randomized Study of Imatinib therapy in chornic phase chronic myeloid leukemia comparing standard dose-escalation with progressive-one (JALSG CML207study)
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 240
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 15years-old 至 70years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Other active neoplasma 2. Severe infection 3. Anticancer drug other than hydoroxurea in 2 weeks 4. Severe psychological disorders such as shizophrenia 5. Pregnant and/or lactating woman 6. Uncontorlled diabetis meritis 7. Acute myocardial infarction in 1 year or history of heart failure 8. Liver chirosis 9. Otherwise eligible
研究者
相似试验
进行中（未招募）
不适用
A RANDOMIZED PHASE III STUDY OF IMATINIB DOSE OPTIMIZATION COMPARED WITH NILOTINIB IN PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA AND SUBOPTIMAL RESPONSE TO STANDARD-DOSE IMATINIBIMATINIB DOSE OPTIMIZATION COMPARED WITH NILOTINIB IN PATIENTS WITH CML AND SUBOPTIMAL RESPONSE TO STANDARD-DOSE IMATINIBMedDRA version: 9.1Level: LLTClassification code 10009012Term: Chronic myelogenous leukemiaEUCTR2008-007054-35-FIovartis Pharma Services AG188
进行中（未招募）
不适用
A clinical study which compares the benefit of optimizing the dose ofimatinib (Gleevec/Glivec) with Nilotinib (Tasigna) in patients with chronicmyelogenous leukemia who have not optimally responded to standardtreatment with Imatinib.IMATINIB DOSE OPTIMIZATION COMPARED WITH NILOTINIB IN PATIENTS WITH CML AND SUBOPTIMAL RESPONSE TO STANDARD-DOSE IMATINIBMedDRA version: 14.1Level: LLTClassification code 10009012Term: Chronic myelogenous leukemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2008-007054-35-DEovartis Pharma Services AG188
已完成
3 期
Chronic MyelogenousLeukemia Suboptimal Response Study.CTRI/2011/05/001752ovartis HealthCare Private Limited
已完成
不适用
A Randomized Phase Lll Study of Imatinib Dose Optimization Compared With Nilotinib in Patients With Chronic Myelogenous Leukemia and Suboptimal Response to Standard-dose ImatinibPER-023-09OVARTIS BIOSCIENSES PERU S.A.,
进行中（未招募）
1 期
A randomised Phase II trial of Imatinib (IM) versus Hydroxychloroquine (HCQ) and IM for patients with Chronic Myeloid Leukaemia (CML) in Major Cytogenetic Response (MCyR) with residual disease detectable by quantitative polymerase chain reaction (Q-PCR) - CHOICES-CHlOroquine and Imatinib Combination to Eliminate Stem cellsChronic Myeloid LeukaemiaMedDRA version: 15.0Level: PTClassification code 10009013Term: Chronic myeloid leukaemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-014373-41-DEClinical Trial Center Aachen76